Recent Advances in Nanomedicines for Multiple Sclerosis Therapy

Zeng, Yujun; Li, Zhiqian; Gu, Zhongwei; Zhang, Hu; Luo, Kui

doi:10.1021/acsabm.0c00953

Cited by 8 publications

(6 citation statements)

References 364 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…therapeutic groups are incorporated into one theranostic agent, this agent could achieve diagnosis, treatment and monitoring of the disease progression with a single administration of this agent [157][158][159][160]. The application of theranostic agents not only decreases the incidence of side effects by reducing the dose for diagnostic and therapeutic treatment, but also achieves real-time monitoring of the treatment procedures so as to enhance the accuracy of operations [161][162][163][164]. SPIONs, as a promising T 2 contrast agent for MS diagnosis, could also be employed to achieve therapeutic effects.…”

Section: Emerging Theranostics Of Ms With Nanomedicinesmentioning

confidence: 99%

Recent advances in development of nanomedicines for multiple sclerosis diagnosis

Zhang¹,

Dai²,

Hu³

et al. 2021

Biomed. Mater.

Self Cite

View full text Add to dashboard Cite

Multiple sclerosis (MS) is a neurodegenerative disease with a high morbidity and disease burden. It is characterized by the loss of the myelin sheath, resulting in the disruption of neuron electrical signal transmissions and sensory and motor ability deficits. The diagnosis of MS is crucial to its management, but the diagnostic sensitivity and specificity are always a challenge. To overcome this challenge, nanomedicines have recently been employed to aid the diagnosis of MS with an improved diagnostic efficacy. Advances in nanomedicine-based contrast agents in magnetic resonance imaging scanning of MS lesions, and nanomedicine-derived sensors for detecting biomarkers in the cerebrospinal fluid biopsy, or analyzing the composition of exhaled breath gas, have demonstrated the potential of using nanomedicines in the accurate diagnosis of MS. This review aims to provide an overview of recent advances in the application of nanomedicines for the diagnosis of MS and concludes with perspectives of using nanomedicines for the development of safe and effective MS diagnostic nanotools.

show abstract

Section: Emerging Theranostics Of Ms With Nanomedicinesmentioning

confidence: 99%

Recent advances in development of nanomedicines for multiple sclerosis diagnosis

Zhang¹,

Dai²,

Hu³

et al. 2021

Biomed. Mater.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Examples are mentioned in the literature for such application. A bifunctional peptide (small and soluble) and PLGA NPs (large and insoluble) resulted in relative greater EAE suppression [ 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 ].…”

Section: Applied Strategies Utilized Against Msmentioning

confidence: 99%

“…The utilized strategies to approach the disease are (Figure 1): (a) Use linear MBP, PLP, and MOG epitopes with or without amino acid mutations to gain insights into the molecular basis of the disease. This information is aided by nuclear magnetic resonance (NMR) studies and structural information of the epitope ligand bound to the MHC [19]; (b) Perform cyclization of these epitopes to increase their stability [20][21][22][23][24][25][26]; (c) Conjugate selective epitopes with mannan [27][28][29][30]; (d) Synthesis of non-peptide mimetic analogs to decrease their flexibility and increase their therapeutic index; (e) Apply nanotechnology as a means of antigen delivery [31][32][33][34][35][36][37][38][39] Brain Sci. 2021, 11, x FOR PEER REVIEW 2 of 15 degenerative disease is initiated by autoreactive T helper (Th) cells and affects approximately 2.5 million people worldwide.…”

Section: Introductionmentioning

confidence: 99%

Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan

et al. 2021

View full text Add to dashboard Cite

Multiple Sclerosis (MS) is a serious autoimmune disease. The patient in an advanced state of the disease has restrained mobility and remains handicapped. It is therefore understandable that there is a great need for novel drugs and vaccines for the treatment of MS. Herein we summarise two major approaches applied for the treatment of the disease using peptide molecules alone or conjugated with mannan. The first approach focuses on selective myelin epitope peptide or peptide mimetic therapy alone or conjugated with mannan, and the second on immune-therapy by preventing or controlling disease through the release of appropriate cytokines. In both approaches the use of cyclic peptides offers the advantage of increased stability from proteolytic enzymes. In these approaches, the synthesis of myelin epitope peptides conjugated to mannan is of particular interest as this was found to protect mice against experimental autoimmune encephalomyelitis, an animal model of MS, in prophylactic and therapeutic protocols. Protection was peptide-specific and associated with reduced antigen-specific T cell proliferation. The aim of the studies of these peptide epitope analogs is to understand their molecular basis of interactions with human autoimmune T-cell receptor and a MS-associated human leucocyte antigen (HLA)-DR2b. This knowledge will lead the rational design to new beneficial non-peptide mimetic analogs for the treatment of MS. Some issues of the use of nanotechnology will also be addressed as a future trend to tackle the disease. We highlight novel immunomodulation and vaccine-based research against MS based on myelin epitope peptides and strategies developed in our laboratories.

show abstract

“…These nanomedicines selectively accumulate in tumour tissues to realize a selective and efficient therapeutic effect ( Fig. 1A ) ( 29 ). Furthermore, it has been indicated that the adoption of NPs can effectively change the acoustic environment (tissue structure, density, blood supply and functional state on ultrasonic transmission and energy deposition during HIFU treatment) of tumour tissues ( 30 ), making them more sensitive to HIFU, resulting in greater ablative efficacy with the same or lower HIFU irradiation doses.…”

Section: Introductionmentioning

confidence: 99%

Nanomedicines for high‑intensity focused ultrasound cancer treatment and theranostics (Review)

Zheng¹,

Xia²,

Huang³

et al. 2023

Exp Ther Med

View full text Add to dashboard Cite

High-intensity focused ultrasound (HIFU) is a promising and representative non-invasive therapeutic method for treating cancer with a high degree of efficacy. This non-invasive method induces tumour cell necrosis by increasing the local temperature and mechanical pressure. However, the clinical application of HIFU is limited given its low penetration depth and the incidence of off-target side effects. With their promising structural adjustability and targeting ability, nanomedicines have been adopted to improve the ablative efficacy of HIFU in the treatment of cancer. By selectively changing the acoustic environment (tissue structure, density and blood supply) of tumour tissue, these nanomedicines may allow for lower HIFU doses and treatment duration, while additionally achieving a higher degree of efficacy. The use of nanomedicines may also enable cancer theranostics of HIFU, allowing for precise cancer therapeutics. The present review aimed to provide an overview of advances in nanomedicines for HIFU cancer treatment and theranostics, stating their current limitations and future perspectives. Contents 1. Introduction 2. Nano-therapeutics for HIFU-based cancer treatment 3. Nano-based HIFU cancer theranostics 4. Conclusions and future perspectives

show abstract

Recent Advances in Nanomedicines for Multiple Sclerosis Therapy

Cited by 8 publications

References 364 publications

Recent advances in development of nanomedicines for multiple sclerosis diagnosis

Recent advances in development of nanomedicines for multiple sclerosis diagnosis

Novel Approaches in the Immunotherapy of Multiple Sclerosis: Cyclization of Myelin Epitope Peptides and Conjugation with Mannan

Nanomedicines for high‑intensity focused ultrasound cancer treatment and theranostics (Review)

Contact Info

Product

Resources

About